Stephanie The

Stephanie The

Auto-generated profile, based on publicly available information

Stephanie The

Cancer Data Science Shared Resource, Department of Biostatistics, University of Michigan School of Public Health, Ann Arbor, MI, USA

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 April 2023 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
ECEileen Carpenter
Eileen Carpenter
AEAhmed M. Elhossiny
Ahmed M. Elhossiny
PKPadma Kadiyala
Padma Kadiyala
JLJay Li
Jay Li
Jake McGueJake McGue
Jake McGue
MMMarina Pasca di Magliano
Marina Pasca di Magliano
The adult healthy human pancreas has been poorly studied given the lack of indication to obtain tissue from the pancreas in the absence of disease and rapid postmortem degradation. We obtained pancreata from brain dead donors, thus avoiding any warm ischemia time. The 30 donors were diverse in age and race and had no known pancreas disease. Histopathologic analysis of the samples revealed pancreatic intraepithelial neoplasia (PanIN) lesions in most individuals irrespective of age. Using a combination of multiplex IHC, single-cell RNA sequencing, and spatial transcriptomics, we provide the first-ever characterization of the unique microenvironment of the adult human pancreas and of sporadic PanIN lesions. We compared healthy pancreata to pancreatic cancer and peritumoral tissue and observed distinct transcriptomic signatures in fibroblasts and, to a lesser extent, macrophages. PanIN epithelial cells from healthy pancreata were remarkably transcriptionally similar to cancer cells, suggesting that neoplastic pathways are initiated early in tumorigenesis. Significance: Precursor lesions to pancreatic cancer are poorly characterized. We analyzed donor pancreata and discovered that precursor lesions are detected at a much higher rate than the incidence of pancreatic cancer, setting the stage for efforts to elucidate the microenvironmental and cell-intrinsic factors that restrain or, conversely, promote malignant progression. See related commentary by Hoffman and Dougan, p. 1288. This article is highlighted in the In This Issue feature, p. 1275

18 October 2023 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
ECEileen Carpenter
Eileen Carpenter
PKPadma Kadiyala
Padma Kadiyala
AEAhmed M. Elhossiny
Ahmed M. Elhossiny
SKSamantha B. Kemp
Samantha B. Kemp
JLJay Li
Jay Li
MMMarina Pasca di Magliano
Marina Pasca di Magliano
Purpose: Pancreatic ductal adenocarcinoma (PDAC) is generally divided in two subtypes, classical and basal. Recently, single-cell RNA sequencing has uncovered the coexistence of basal and classical cancer cells, as well as intermediary cancer cells, in individual tumors. The latter remains poorly understood; here, we sought to characterize them using a multimodal approach. Experimental Design: We performed subtyping on a single-cell RNA sequencing dataset containing 18 human PDAC samples to identify multiple intermediary subtypes. We generated patient-derived PDAC organoids for functional studies. We compared single-cell profiling of matched blood and tumor samples to measure changes in the local and systemic immune microenvironment. We then leveraged longitudinally patient-matched blood to follow individual patients over the course of chemotherapy. Results: We identified a cluster of KRT17-high intermediary cancer cells that uniquely express high levels of CXCL8 and other cytokines. The proportion of KRT17high/CXCL8+ cells in patient tumors correlated with intratumoral myeloid abundance, and, interestingly, high protumor peripheral blood granulocytes, implicating local and systemic roles. Patient-derived organoids maintained KRT17high/CXCL8+ cells and induced myeloid cell migration in a CXCL8-dependent manner. In our longitudinal studies, plasma CXCL8 decreased following chemotherapy in responsive patients, while CXCL8 persistence portended worse prognosis. Conclusions: Through single-cell analysis of PDAC samples, we identified KRT17high/CXCL8+ cancer cells as an intermediary subtype, marked by a unique cytokine profile and capable of influencing myeloid cells in the tumor microenvironment and systemically. The abundance of this cell population should be considered for patient stratification in precision immunotherapy. See related commentary by Faraoni and McAllister, p. 2297

15 February 2024 in JCI Insight
Verified
Journal Article
Open access
PDF file
QZQiang Zhang
Qiang Zhang
LJLong Jiang
Long Jiang
WWWei-wei Wang
Wei-wei Wang
AHAmanda K. Huber
Amanda K. Huber
VVVictoria M. Valvo
Victoria M. Valvo
MMMeredith A. Morgan
Meredith A. Morgan
Radiotherapy induces a type I interferon–mediated (T1IFN-mediated) antitumoral immune response that we hypothesized could be potentiated by a first-in-class ataxia telangiectasia mutated (ATM) inhibitor, leading to enhanced innate immune signaling, T1IFN expression, and sensitization to immunotherapy in pancreatic cancer. We evaluated the effects of AZD1390 or a structurally related compound, AZD0156, on innate immune signaling and found that both inhibitors enhanced radiation-induced T1IFN expression via the POLIII/RIG-I/MAVS pathway. In immunocompetent syngeneic mouse models of pancreatic cancer, ATM inhibitor enhanced radiation-induced antitumoral immune responses and sensitized tumors to anti–PD-L1, producing immunogenic memory and durable tumor control. Therapeutic responses were associated with increased intratumoral CD8 + T cell frequency and effector function. Tumor control was dependent on CD8 + T cells, as therapeutic efficacy was blunted in CD8 + T cell–depleted mice. Adaptive immune responses to combination therapy provided systemic control of contralateral tumors outside of the radiation field. Taken together, we show that a clinical candidate ATM inhibitor enhances radiation-induced T1IFN, leading to both innate and subsequent adaptive antitumoral immune responses and sensitization of otherwise resistant pancreatic cancer to immunotherapy.

1 April 2023 in Journal of Clinical Oncology
Verified
Journal Article
Open access
CSCorey W. Speers
Corey W. Speers
WSW. Fraser Symmans
W. Fraser Symmans
WBWilliam E. Barlow
William E. Barlow
ATAlex Trevarton
Alex Trevarton
STStephanie The
Stephanie The
ATAlastair Thompson
Alastair Thompson
PURPOSE: Chemotherapy has not demonstrated benefit over adjuvant endocrine therapy alone for postmenopausal patients with node-positive breast cancer with a 21-gene breast recurrence score (RS) of 25 or below (RS ≤ 25). We tested whether combined results from RS and the sensitivity to endocrine therapy (SET2,3) index of endocrine-related transcription (SETER/PR) adjusted for baseline prognostic index (BPI) improve prognostic assessment, and whether SET2,3 predicted benefit from anthracycline-based chemotherapy. METHODS: A blinded retrospective clinical validation of SET2,3 in two randomized treatment arms from the SWOG S8814 trial comparing adjuvant anthracycline-based chemotherapy followed by tamoxifen endocrine therapy for 5 years, versus tamoxifen alone. SET2,3 assay was calibrated and measured using whole-transcriptome RNA sequence of tumor samples already tested for RS. The primary end point was disease-free survival (DFS). RESULTS: There were 106 events in 283 patients over a median follow-up of 8.99 years. Proportional hazards assumptions were met during the first 5 years only. SET2,3 index and RS were not correlated (r = –0.04) and were independently prognostic (SET2,3: hazard ratio [HR], 0.48 per unit; 95% CI, 0.34 to 0.68; P < .001; RS: HR, 1.28 per 10 units; 95% CI, 1.14 to 1.44; P < .001). SET2,3 index did not predict chemotherapy benefit (interaction P = .77). SET2,3 was high in 93/175 (53%) patients with RS ≤ 25 (concordant low-risk), with 5-year DFS 97%. SET2,3 was low in 55/108 (51%) patients with RS > 25 (concordant high-risk), with 5-year DFS 53%. Both components of SET2,3 index were prognostic after adjustment for RS: SETER/PR (HR, 0.65; 95% CI, 0.46 to 0.92) and BPI (HR, 0.45; 95% CI, 0.31 to 0.64). CONCLUSION: SET2,3 index was not correlated with RS, demonstrated additive prognostic performance, and was not chemopredictive in this subset of patients from S8814. The SETER/PR and BPI components of SET2,3 each added prognostic information to RS.

27 March 2026 in Neoplasia
Verified
Journal Article
Open access
SJSangeeta Jaiswal
Sangeeta Jaiswal
STStephanie The
Stephanie The
TCTse-Shao Chang
Tse-Shao Chang
Jiaqi ShiJiaqi Shi
Jiaqi Shi
TWThomas Wang
Thomas Wang
Colorectal cancer (CRC) remains a leading cause of cancer‑related morbidity and mortality worldwide. Although the adenoma-carcinoma sequence and its genetic drivers are well described, the earliest cellular and molecular events initiating tumorigenesis within histologically normal colonic epithelium remain poorly defined. This study aims to identify tumor‑initiating cells (TICs), distinguish them from normal stem‑like cells (nSTMs), and delineate early transcriptional and signaling programs using single‑cell RNA sequencing (scRNA‑seq) from paired normal‑appearing and transformed human colonic tissues. Fresh biopsies from histologically normal mucosa and matched polyps, including tubular adenomas, sessile serrated adenomas, and adenocarcinomas, were collected from seven subjects. Single‑cell transcriptomes were generated using the 10x Genomics platform and analyzed with Seurat, Monocle2, CytoTRACE, GSEA/GSVA, RNA velocity, InferCNV, CellChat, and NicheNet. Spatial validation was performed using RNA‑FISH. We resolved 51,054 high‑quality single‑cell transcriptomes into 33 clusters. Tumor-specific stem-like (tSTM) and deep crypt secretory (tDCS) populations were enriched in adenomas. Subclustering of tSTM identified TIC-like subsets predominantly derived from histologically normal mucosa that localized to the root of lineage trajectories leading to polyp-enriched tSTM states. Compared to nSTMs, TICs exhibited enhanced stemness potential, early epithelial-mesenchymal transition (EMT) and interferon signaling, suppression of oxidative phosphorylation, and distinct genomic and signaling features, indicating early neoplastic reprogramming. ETS2, SLC12A2, and LEFTY1 were identified as TIC‑specific markers; SOD3 and GPRC5A increased along the TIC‑to‑tSTM trajectory. RNA‑FISH confirmed candidate marker localization. Independent validation using the COLONMAP dataset (30 polyps, 35 normal samples) demonstrated that TIC-like cells were predominantly enriched in tubular adenomas but were scarce in serrated lesions. Across this independent cohort, TIC marker genes showed reproducible upregulation in TIC-like populations, supporting the robustness of these observations across cohorts. Our results identify TICs as the origin of neoplastic stem‑like states in the conventional tubular adenoma pathway and define early transcriptional, metabolic, and microenvironmental reprogramming events that distinguish TICs from nSTMs. In contrast to serrated pathways described in other atlases, our data support a stem‑like expansion model for tubular adenomas and nominate biomarkers with translational potential for early CRC detection and intervention.

13 December 2019 in Cancer Research
Verified
Journal Article
Closed access
MHMegan T. Hoffman
Megan T. Hoffman
STStephanie The
Stephanie The
DSDaniel J. Salas-Escabillas
Daniel J. Salas-Escabillas
KDKathleen E. DelGiorno
Kathleen E. DelGiorno
FBFilip Bednar
Filip Bednar
Howard C. CrawfordHoward C. Crawford
Howard C. Crawford
Pancreatic ductal adenocarcinoma (PDA) is the third most common cause of cancer death in the US with a 9% 5-year survival rate. PDA is characterized by a robust stromal reaction, a large portion of which is composed of infiltrating immune cells and supported by fibroblasts. This fibroinflammatory response promotes both the initiation and progression of PDA. Key to this progression is the crosstalk between the tumor epithelium and immune compartment. Metaplastic tuft cells (MTCs) are a subset of the neoplastic epithelium derived by the transdifferentiation of acinar cells. Tuft cells have been characterized to have a “sense-and-respond” role in luminal surfaces throughout the body, using the taste chemosensory system to promote an inflammatory response in infected and damaged tissues. Among the pancreatic epithelium, MTCs uniquely express components of the gustation sensory system including taste receptors, TRPM5 and αGustducin, as well as an array of inflammatory cytokines, suggesting they are capable of promoting an immune response to extracellular challenges. To explore this hypothesis, we ablated αGustducin, a key protein in the chemosensory cascade, in a model of pancreatitis-associated tumorigenesis. We found that neoplasia in the GNAT3-/-; KrasG12D; PTF1aCreERT mice initiates and progresses more rapidly, a difference associated with alteration in immune cell subtypes. To further quantitate changes in the immune response, we performed mass cytometry (CyTOF), as a way to explore changes in cell number and type, and single-cell sequencing, to more deeply probe the unique gene signatures of cells within the tumor stroma. These large-scale analyses suggest substantial changes in the number of T-cell and myeloid cell populations, as well as alterations of fibroblasts and myeloid cell polarity. We conclude that MTCs use chemosensory signaling to promote the formation of a tumor-suppressive microenvironment. Citation Format: Megan T. Hoffman, Stephanie The, Daniel J. Salas-Escabillas, Kathleen E. DelGiorno, Filip Bednar, Robert F. Margolskee, Arvind Rao, Howard C. Crawford. The role of metaplastic tuft cell chemosensory signaling in pancreatic cancer [abstract]. In: Proceedings of the AACR Special Conference on Pancreatic Cancer: Advances in Science and Clinical Care; 2019 Sept 6-9; Boston, MA. Philadelphia (PA): AACR; Cancer Res 2019;79(24 Suppl):Abstract nr A19.